BCLI Stock — Brainstorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc (BCLI)

Updated October 16, 2026.

BCLI is a Stock. Total return is 1633.8% over the past 23.4 years, 511.0 points ahead of SPY at 1122.8%.

Brainstorm Cell Therapeutics is a biotechnology company developing autologous cellular therapies for neurodegenerative diseases, primarily through its proprietary NurOwn platform that uses cultured bone marrow-derived mesenchymal stem cells to deliver neurotrophic factors and modulate disease processes. The company has advanced NurOwn through Phase IIIb trials for amyotrophic lateral sclerosis, Phase II trials for progressive multiple sclerosis, and earlier-stage development for Alzheimer's disease and other neurological conditions. This is a clinical-stage biotech company with no established distribution history, appealing primarily to investors seeking exposure to early-stage therapeutic development rather than current income.

BCLI performance versus SPY

Price and return data through 2026-10-16.

Total return is 1633.8% over the past 23.4 years, 511.0 points ahead of SPY at 1122.8%. Over the past year its total return — price change plus distributions reinvested — is 16.5%. Its deepest 1-year drawdown was 46.5%.

BCLI key facts

Asset type

Stock

Asset class

Equity

Inception date

05/28/2003

Distribution frequency

None

Last close

$0.78 (as of 2026-10-16)

Market cap

$8,609,331

Average volume

2491.0

Beta

0.262

Payout ratio

0.0%

EPS

$-0.93

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BCLI risks and drawbacks

The deepest 1-year drawdown on record here is 46.5%.

Who may consider BCLI — and who may not

It is a weaker fit for investors who need monthly cash flow (BCLI does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on BCLI

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions